Phase 1/2 Evaluation of Adenoviral p53 (Ad-p53) in Combination With Capecitabine (Xeloda) or Anti-PD-1 in Patients With Unresectable Liver Metastases of Colorectal Carcinoma(CRC) and Other Solid Tumors, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) and Primary Hepatic Cancers With Known Disease Progression on Standard Therapy
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Safety assessed by CTCAE
研究概览
简要总结
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal carcinoma (CRC) and other solid tumors, including primary hepatocellular carcinoma (HCC). A third arm will study the intra-tumoral injection of Ad-p53 combined with nivolumab infusions in recurrent head and neck squamous cell cancer (HNSCC). This safety study has a standard 3+3 design for arms A and B; .HNSCC will be placed in a single dosing cohort. The Maximum Tolerated Dose (MTD) will be determined as well for intra-arterial infusions, and the entire study will determine the general efficacy using RECIST 1.1 and Immune-Related Response Criteria. Safety will be followed using the CTCAE listings for adverse events.
详细描述
This is a Phase 1/2 study split into 3 arms. Arm A will follow the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine while Arm B follows the intra-arterial administration of Ad-p53 combined with pembrolizumab, both in patients with unresectable, refractory liver metastases of colorectal carcinoma (CRC) and other solid tumors, including primary hepatocellular carcinoma (HCC). Arm C will follow the combination of intra-tumoral injections of Ad-p53 and nivolumab infusions. Arms A and B have a standard 3+3 design, with dosing following the initial cohort determined by MTD and DLT criteria as well as safety and tolerance. Arm C will be a single dosing cohort followed for safety and efficacy. All patients will be followed for adverse events and preliminary efficacy. In Arms A and B, the Maximum Tolerated dose (MTD) will be determined. All patients will be followed for general safety and preliminary efficacy using RECIST 1.1 and Immune-Related Response Criteria. CEA levels will also be followed for patients with metastatic colo-rectal cancer. Biomarker testing of archival or fresh tissue is performed during the study. In Arms A and B, patients will undergo a maximum of 2 8-week cycles, with scans every 8 weeks. For Arm B, patients will undergo a maximum of 3 28-day Cycles. All patients will continue on the background therapy for any additional cycles. No additional biopsies are planned following Screening. Enrollment will be up to 24 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Male or female, age 18 or above, who agree to use barrier contraception throughout the study. Females of child-bearing potential must be non-pregnant and non-lactating throughout the study.
- •Histologically or cytologically confirmed solid tumors or hepatocellular carcinoma with known disease progression.
- •Each patient entered on the study must have disease that is evaluable for response using RECIST 1.1 criteria with a minimum size of 1 cm by CT/MRI or physical examination
- •Carcinoma patients in Arm A or Arm B must have received at least 1 prior regimen of standard of care systemic antitumor therapy for their metastatic disease and experienced tumor progression within 3 months after the last prior administration of the therapy or experienced unacceptable toxicity to these treatments.
- •Subjects in Arm A and Arm B should have measurable CT evidence of liver metastases or liver lesions that are not treatable by surgical resection or local ablation in consultation with hepatobiliary specialist.
- •The maximum tumor diameters for each Cohort for both Arm A and Arm B should achieve a dose of approximately 1x1011 viral particles (vp)/cm3 of tumor volume. (see Table 1). Please refer to Table for calculating tumor volume.
- •ECOG Performance Status 0 - 1
- •Either no brain metastases or irradiated stable brain metastases
- •Life expectancy at least 3 months
- •No prior autologous or allogeneic organ or tissue transplantation
- •PT/international normalized ratio (INR) ≤ULN; aPTT ≤ULN.
- •ANC ≥1500 cells/mm3
- •Platelet count ≥100,000 cells/mm3
- •Hemoglobin ≥9.0 g/dL
- •Creatinine <2.0 mg/dL or creatinine clearance ≥50 mL/min
- •Total bilirubin <1.5 x ULN
- •AST and ALT <3.0 x ULN
- •Alkaline phosphatase ≤5 x ULN
- •Negative pregnancy test in women of childbearing potential
- •Fertile patients must use effective contraception
- •No non-approved investigational agents or procedures ≤4 weeks of study entry
- •Patients with PRIMARY HEPATIC CANCER must have an undetectable viral load for Hepatitis B and C.
- •Patients with Primary Hepatic Cancer have not recently been treated with antivirals.
- •Troponin blood level within normal limits.
- •Favorable biomarker profile defined by either wild type p53 gene sequence or less than 20% p53 positive tumor cells by immunohistochemistry
- •Echocardiogram with normal ejection fractions
- •Normal lung oxygen saturation by pulse oximeter, as determined by the Principal Investigator based on patient history and status.
- •Arm C patients must have loco-regional recurrent head and neck squamous cell carcinoma (HNSCC), excluding endolaryngeal recurrence, meeting the following criteria:
- •Tumor progression within 6 months of platinum-based chemotherapy
- •All HNSCC lesions should be in the head and neck region and suitable for intra-tumoral injection
- •The total sum of Ad-p53 Injection Doses (mL) based upon the tumor volumes shown in Table 2 should be less than or equal to 25 mL as the MTD of Ad-p53 is 2.5 x1013 vp/treatment day.
- •Exclusion Criteria
- •Subjects must not be candidates for hepatic surgery or locoregional therapy of liver tumors with curative intent.
- •Liver tumors must not be estimated to invade approximately more than one-third of the liver.
- •Liver tumor-directed therapy, hepatic surgery, antibody-based therapy, or immunotherapy must not have been performed < 28 days, chemotherapy < 21 days, and targeted small molecule therapy or hormonal therapy < 14 days prior to enrollment. No radiation to tumor sites during the last 4 weeks.
- •No macroscopic intra-vascular invasion by tumors of the main portal vein, hepatic vein or vena cava.
- •Chronic liver dysfunction prior to development of liver metastases (Child-Pugh C or greater).
- •Active alcohol dependence
- •Prior radiation performed to areas of measurable disease ≤ four weeks of study entry unless there is documented evidence of disease progression.
- •Use of systemic anti-cancer therapy ≤ 4 weeks, or six weeks if the systemic therapy contains a nitrosourea or mitomycin C.
- •Neuropathy (≥grade 2 CTCAE)
- •History of allergic reactions to any components of the treatments
- •Prior additional malignancy within 2 years except for non-melanoma skin cancer, carcinoma in situ of the breast, oral cavity or cervix.
- •Severe, active comorbidity, including any of the following:
- •Active clinically serious infection requiring intravenous antibiotics at the time of study entry (CTCAE Grade 2)
- •Hepatic insufficiency not due to tumor resulting in clinical jaundice or bilirubin >1.5 x ULN and/or coagulation defects
- •Thrombotic or embolic event within the last 6 months including portal vein thrombosis
- •Must not require concomitant treatment with anticoagulants
- •QTcb >470 ms
- 另有 10 项未显示
排除标准
- 未提供
研究组 & 干预措施
Ad-p53 with Xeloda 33.3% of patients
Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and daily metronomic Xeloda (capecetabine), at a dose of 625 mg/m2 BID continuously.
干预措施: Ad-P53 (Drug)
Ad-p53 with Xeloda 33.3% of patients
Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and daily metronomic Xeloda (capecetabine), at a dose of 625 mg/m2 BID continuously.
干预措施: Xeloda (Drug)
Ad-p53 with Keytruda 33.3% of patients
Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and infusions of pembrolizumab every 3 weeks.
干预措施: Ad-P53 (Drug)
Ad-p53 with Keytruda 33.3% of patients
Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and infusions of pembrolizumab every 3 weeks.
干预措施: Keytruda (Drug)
Ad-p53 with Opdivo 33.3% of patients
Up to 12 patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks.
干预措施: Ad-P53 (Drug)
Ad-p53 with Opdivo 33.3% of patients
Up to 12 patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks.
干预措施: Opdivo (Drug)
结局指标
主要结局
Safety assessed by CTCAE
时间窗: Screening to 30-days following Final Treatment (approximately 22 weeks)
Incidence of treatment-emergent and treatment-related adverse events (all AEs, laboratory AEs, SAEs and Fatal AEs, in accordance with the CTCAE
Incidence of dose-limiting toxicities (DLTs)
时间窗: Day 1 to 30-days Following Last Treatment (approximately 21 weeks)
To evaluate the safety, as assessed by the incidence of dose limiting toxicities, of the combination of Ad-P53 and Xeloda or Ad-p53 and Keytruda
Determination of maximum-tolerated dose (MTD)
时间窗: Day 1 to 30 days following Final Treatment (Approximately 21 Weeks)
Determination of maximum tolerated dose (MTD) by review of DLTs, of the combination of Ad-p53 and Xeloda or Ad-p53 and Ketruda
Progression-Free Survival (PFS) of patients using RECIST 1.1
时间窗: Time Frame: Day 1 to progression through end of study, approximately 18 months
PFS in patients treated with Ad-p53 and nivolumab determined by review of scans every 8 weeks for disease progression in accordance with RECIST 1.1. Scans are read locally but kept for possible central review. Scans are done every 8 weeks. Sites will review questionable findings on scans with Immune Related Response Criteria (irRC) \[Wolchok 2009\].
次要结局
- Progression-Free Survival (PFS) of patients using RECIST 1.1(Day 1 to progression through end of study, approximately 2 years)
- Efficacy determined by Immune Related Response Criteria (irRC) [Wolchok 2009](Day 1 of Treatment through 30-days following last treatment (20 weeks))
- Efficacy as determined by biomarker testing and immunohistochemistry testing(Day 1 of Treatment to End of Study (approximately 18 months))